Long-COVID syndrome-associated brain fog and chemofog: Luteolin to the rescue

143Citations
Citations of this article
349Readers
Mendeley users who have this article in their library.

Abstract

COVID-19 leads to severe respiratory problems, but also to long-COVID syndrome associated primarily with cognitive dysfunction and fatigue. Long-COVID syndrome symptoms, especially brain fog, are similar to those experienced by patients undertaking or following chemotherapy for cancer (chemofog or chemobrain), as well in patients with myalgic encephalomyelitis/chronic fatigue syndrome (ME/CFS) or mast cell activation syndrome (MCAS). The pathogenesis of brain fog in these illnesses is presently unknown but may involve neuroinflammation via mast cells stimulated by pathogenic and stress stimuli to release mediators that activate microglia and lead to inflammation in the hypothalamus. These processes could be mitigated by phytosomal formulation (in olive pomace oil) of the natural flavonoid luteolin.

Cite

CITATION STYLE

APA

Theoharides, T. C., Cholevas, C., Polyzoidis, K., & Politis, A. (2021, March 1). Long-COVID syndrome-associated brain fog and chemofog: Luteolin to the rescue. BioFactors. Blackwell Publishing Inc. https://doi.org/10.1002/biof.1726

Register to see more suggestions

Mendeley helps you to discover research relevant for your work.

Already have an account?

Save time finding and organizing research with Mendeley

Sign up for free